Document:

Exhibit 10.8

 

  

 

EMPLOYMENT AGREEMENT

 

BETWEEN

 

PHARMALINK AB

 

AND

 

JOHAN HÄGGBLAD

  

 

May 1,
2017

 

     

     

    

 

EMPLOYMENT AGREEMENT

 

This Employment Agreement (the “Agreement”)
is effective as of May 1, 2017, (the “Effective Date”) BETWEEN:

 

Pharmalink
AB, (556659-9766) Wallingatan 26B, 111 24 Stockholm (“Pharmalink”); and Johan Haggblad [***]
the (“Employee”)

 

	1.	Background, Position and Responsibility

 

		1.1	The Employee has been employed as Chief Executive
Officer (Sv:VD) for Pharmalink through an employment agreement dated January 30,2007 (‘the “CEO Contract”) By
way of this Agreement the parties now amicably agree that the Employee as of the Effective Date .shall instead be employed as
Senior VP of Licensing, IP & legal at Pharmalink.

 

	 	 	
        Accordingly, as of the Effective Date this
        Agreement;

        (i) terminates, supersedes and
        replaces the CEO Contract and neither party shall have any claims against the other based on the CEO Contract or termination
        thereof, except that the Employee’s obligations under Sections 13 Intellectual Property and 14 Confidentiality in the
        CEO Contract shall remain in force to the extent accrued prior to the Effective Date, but

        (ii) does not terminate the
        Employee’s employment with Pharmalink and is not a termination of employment entitling the Employee to any compensation
        or other benefit.

 

		1.2	The Employee is employed as Senior VP of licensing,
IP & Legal for Pharmalink and shall report to the Chief Executive Officer (Sv:VD) for Pharmalink. The employment materially includes all
                                                                                reasonably industry standard duties and obligations such a position of a business of this size and Specifically
                                                                                focuses on administration and management of all licensing related transactions as well as any development or exploratory
                                                                                work which could potentially lead to complementary or new patents or related protection pertaining to the business.

 

		1.3	The employment; is on a full time basis, shall commence May 1, 2017 and shall continue until the end of the termination period
following termination in accordance with Article 7.

 

		1.4	The Employee shall materially perform the employment in Stockholm but acknowledges and accepts that the employment may from
time to time include significant travel time.

 

	2.	Loyalty

 

		2.1	This Agreement is based on mutual loyalty and trust
During the term of the Agreement the Employee shall always promote
and protect the interests of Pharmalink and shall not be engaged in providing services, promoting or otherwise facilitating any
activities which may have a prejudicial effect on the duties associated with the position in Pharmalink.

 

		2.2	Unless otherwise approved in writing by Pharmalink
on a case by case basis, the Employee shall devote all his working time to Pharmalink and shall
not be engaged in providing services, promoting or otherwise facilitating any other business activity, irrespective of whether
such business competes with Pharmalink or not. 

 

		2.3	The Employee warrants that he is not engaged in any
activity in conflict with this Section when signing this Agreement.

 

	3.	Remuneration and benefits

 

		3.1	The Employee is entitled to a monthly base salary
of SEK 130 000 (the “Base Salary”). The Base Salary shall be paid monthly in arrears on dates
according to the regular salary routines of Pharmalink. No compensation shall be paid for overtime
work as this has been accounted for in establishing the Base Salary.

 

     

     

    

  

		3.2	The Base Salary of the Employee shall be subject to annual review, commencing January 2018, taking into account the
                                                                                                                                                 Employee’s performance during the previous year.

 

		3.3	Subject to prior approval in each case Pharmalink shall reimburse the Employee for reasonably necessary and approved business
expenses in connection with performance of the Employee’s duties. Requests for reimbursement for such expenses shall be accompanied
by appropriate documentation. The Employee shall maintain records and written receipts as reasonably requested by Pharmalink lo
substantiate such expenses.

 

		3.4	Bonus Plan. Pharmalink shall for each calendar year establish a personal bonus plan for the Employee based on one or
several milestones to be achieved during such calendar year including a scale with the possibility for the Employee to receive
a bonus salary of up to 25% of the Base Salary based on how many of the milestones are achieved (the “Bonus Plan”).
It is expressly understood that the Bonus Plan is established by Pharmalink meaning that selection of, and scale of value far each
milestone event shall be exclusively determined by Pharmalink at its sole discretion.

 

		3.5	The Employee is entitled to 6 weeks (30 days) paid
annual leave.

 

		3.6	Pharmalink
                                                                                                                                                                               shall pay a monthly premium equal to 20 per cent of the Employee’s Base Salary to an occupational pension insurance
                                                                                                                                                                               (SW: tjänstepensiönsförsäkring) designated by the Employee.

 

		3.7	In case of the Employee’s absence due to sickness, the provisions of the Swedish Sick Pay Act (1991:1047) (SW: lagen
om sjuklön) and the Swedish regulations on Sickness Benefit (SW: Sjukpenning) shall apply. The Employee shall be registered at
the Swedish regional social insurance office (SW: Svcnsk Försäkringskassa). Additionally Pharmalink shall pay the following compensation
during the Employee’s such absence after deduction of what the Employee is entitled to receive from any other insurance including
Försäkringskassan: (i) Day 1; Nothing, “waiting
day”. (SW: karensdag.)

(ii) Day 2-90; 90% of the Base Salary

(iii) Day 91 and onwards Pharmalink shall not pay any
compensation.

 

	4.	Intellectual Property and Results

 

		4.1	All rights to any data, information, material and results, and all intellectual properly rights related thereto, made, written,
designed or produced by the Employee during the term of this Agreement (the “Results”) shall be vested in and owned
by Pharmalink without any further compensation to the Employee than the Base Salary. For the avoidance of doubt, Pharmalink shall
without any restrictions have the right to freely develop, alter, license assign and otherwise dispose Results at Pharmalink’s
discretion.

 

		4.2	The Employee has no right to directly or indirectly in any way use or exploit the Results during the term of his employment
or thereafter unless a written agreement regarding such use has been entered into with Pharmalink.

 

		4.3	The Employee agrees and undertakes without any additional compensation to execute all such deeds and documents that, in Pharmalink’s
sole discretion, arc necessary or desirable in order for Pharmalink to be able to protect, register, maintain and in any other
way be able to fully enjoy Pharmalink’s rights to Results.

 

	5.	Confidentiality

 

		5.1	The Employee undertakes to not at any time during
the employment or afterwards utilise or disclose (unless required by the performance of the duties
under the employment  agreement with Pharmalink, by law or through written permission from Pharmalink) any information relating
to Pharmalink or any of its associated companies that Pharmalink reasonably wishes to keep confidential, including but not limited
to, information concerning Pharmalink’s or any associated company’s science projects, affairs, business plans, agreements,
profitability, operations, experience,investigation methods, personnel, business concepts,
marketing campaigns, etc.

 

     

     

    

 

		5.2	All business records, information, papers and documents kept or made by the Employee during the employment, relating to the
business of Pharmalink, shall be and remain the property of Pharmalink at all times. At any time upon the request of Pharmalink,
the Employee shall promptly deliver to Pharmalink, and shall retain no copies of, any written materials, records and documents
made by him or otherwise in her possession while employed by Pharmalink concerning the business or affairs of Pharmalink other
than personal materials, records and documents not containing proprietary information relating to such business or affairs.

 

		5.3	The Employee’s obligations of confidentiality and non-use are not limited in time and shall remain in force after the
employment has ceased with Pharmalink.

 

	6.	Non Competition

 

		6.1	During the term of the Agreement the Employee undertakes not to, without the prior written
                                                                                                                                                  consent of Pharmalink, make preparations or carry out, directly or indirectly, any business or activity which competes or
                                                                                                                                                  conflicts with Pharmalink, or in other manners, directly or indirectly, accept employment, perform services or acquire
                                                                                                                                                  ownership in any business or activity that carries out such business or activity or in other ways assist such business or
                                                                                                                                                  activity. However, the Employee is allowed to invest in generally available funds or investment companies that on an
                                                                                                                                                  independent discretionary basis invest in companies with business similar to Pharmalink. In addition the Employee is allowed
                                                                                                                                                  to invest in companies similar to Pharmalink for the sole purpose of it being a financial investment for the purpose of
                                                                                                                                                  financial gains and subject to that no such investment results in; (i) a direct or indirect ownership of more than 10% in any
                                                                                                                                                  single company nor (ii) any activity in relation to such company that would except for the investment otherwise be a breach
                                                                                                                                                  of this Section 6.1.

 

		6.2	Pharmalink shall have the right and option to enforce the restrictions of non-competition in Section 6.1 for a period
of 12 months following the term of this Agreement. During such period the Employee shall notify Pharmalink in writing at least
45 days prior to undertaking any activity that may conflict with Section 6.1. In the event Pharmalink approves in writing or does
not respond within the 45 day period the requested activity shall he considered approved. In the event Pharmalink disapproves
in writing within the 45 day period the Employee may not undertake the requested activity and Pharmalink shall in such case as
compensation for the inconvenience which the restriction entails pay to the Employee each month the difference between the Base
Salary on the date on which her employment ceased, and all other compensations which the Employee subsequently earns directly or
indirectly in any new activity. However, the payment shall at no time exceed sixty (60) percent of the Base Salary and it shall
be payable only during the period which Pharmalink selects at its discretion to enforce the non-competition restrictions.

 

		6.3	The Employee undertakes during the employment and
12 months thereafter not to:  (i) directly or indirectly
employ, try to recruit, entice away or solicit personnel of Pharmalink or any group company or influence such personnel to end
their employment in the Pharmalink or any group company; nor

(ii) establish business relationships with any of
Pharmalink’s or any group company’s business partners or prospects (defined as customers, investor’s,
licensees or other partner aiming to acquire any business right to Pharmalink) or weaken such partner’s relationship
with Pharmalink or any group company. The Employee is however allowed to establish business relationships with
Pharmalink’s suppliers and service providers.

 

	7.	Term and Termination

 

		7.1	This Agreement shall remain in force from the date
of signature below until the end of the termination period following termination in accordance
with this Article 7.

 

		7.2	This Agreement shall terminate automatically without
any compensation on the last day of the month when the Employee turns 65 years old.

 

     

     

    

		7.3	Each party shall have the right to terminate this
Agreement for material breach by the other party by giving 30 days prior written notice.

 

		7.4	Each party shall have the right to terminate this Agreement without cause by giving the other party written notice of such
termination; (i) in case of termination by the Employee
with 6 months prior written notice,

(ii) in the case of termination by Pharmalink with 12 months
prior written notice, and

(iii) the Employee shall be obligated to continue to work
and carry out the obligations of the employment for 6 months following notice of such termination and shall thereafter have
no further obligation to carry out any work or other services for Pharmalink.

 

		7.5	Following any notice of termination of this Agreement Pharmalink shall at its discretion have the
right to remove and relieve the Employee from his position and restrict access to any facility and information of Pharmalink.

 

		7.6	Following termination of this Agreement, or at earlier the request of Pharmalink, the Employee agrees to return all tangible
information, reports, papers, documents and any other property, including copies and duplicates thereof, which were entrusted to
him or which came into his possession in connection with the employment.

 

		7.7	Termination of this Agreement shall not affect rights and obligations that have accrued prior to such termination, and Articles
4, 5, 6, 7, 8 and 9 shall survive any termination or expiry of this Agreement.

 

	8.	Governing Law and Dispute resolution

 

		8.1	This Agreement shall be governed by laws of Sweden without regard to its principle of conflict of laws.

                                                                      

                                                                     Any dispute, controversy or claim arising out of or in connection with this Agreement or the breach, termination or invalidity thereof shall be finally solved by arbitration at the Arbitration Institute of the Stockholm Chamber of Commerce.

 

		8.2	The rules for expedited arbitrations shall apply, unless the Arbitration Institute, taking into account the complexity of the
case, the amount in dispute and other circumstances, determines that the general rules for arbitration of the Institute shall apply.
In the latter case, the Institute shall also decide whether the tribunal shall be composed of one or three arbitrators. The arbitral
proceedings shall be held in Stockholm, Sweden. The language used in the arbitral proceedings shall be Swedish.

 

		8.3	Each party undertakes to keep confidential (a) all orders and awards in the arbitration, together with (b) all materials submitted
in the arbitration proceedings and created for the purpose of the arbitration and (c) all other documents submitted by the other
party in the arbitration proceedings unless such documents are already in the public domain. Exceptions to the foregoing shall
only apply to the extent that disclosure may be required of a party (i) due to mandatory law, an order of a competent court or
public authority, or (ii) to protect, fulfill or pursue a legitimate legal right or obligation or (iii) to enforce or challenge
an award.

 

		8.4	The cost of the arbitration tribunal shall be borne by Pharmalink, unless it is determined by the arbitrator(s) that the Employee
without reasonable cause initiated the dispute. Each respective party’s trial related costs and expenses such as attorney’s,
advisor’s and evidence (sv: Rättegängskostnader”) shall be paid and allocated according to the the Swedish Code of
Judicial Procedure (sv: Rättegängsbalken”).

 

	9.	Entire Agreement

                                                                                 

                                                                                This Agreement may only be amended or changed by an instrument in writing duly executed and signed by the parties.

 

 

     

     

    

 

This Agreement has been executed in two (2) original counterparts,
of which the parties have taken one each

 

	Date 	Aug. 3, 2017	 	 
	 	 	 
	Pharmalink AB	 	 
	 	 	 
	 	 	 
	/s/
    Bengt Julander	 	/s/
    Johan Häggblad
	Bengt Julander (Chairman
    of the Board)	 	Johan HäggbladExhibit 10.9

 

EMPLOYMENT AGREEMENT

 

Between Pharmalink AB, 556659-9766 ("The Company"),
Wallingatan 26B, 111 24 Stockholm and

Fredrik Johansson [***] has signed the following employment
contract.

 

	1.	Work duties, form of employment, etc.

 

	1.1	JOHANSSON is employed as CFO. JOHANSSON will work full time in the Company and report to the
Company's CEO. Normal working hours are 40 hours per week.

 

	1.2	The employment is a permanent employment and is valid from August 1, 2017 or earlier if agreed between the parties.

 

	1.3	JOHANSSON will carry out all parts of his work with the skill, speed and care that the Company has reason to expect from a
reputable CFO.

 

	2.	Salary, overtime, etc.

 

	2.1	JOHANSSON receives a salary of SEK 115,000 per month. The salary is paid on the 25th of the earning month. If the 25th is a
holiday, the salary will be paid the following weekday.

 

		In addition to salary, JOHANSSON receives 16.3% of monthly salary per month in pensions and
                                                                               insurance benefits, in addition to statutory pensions and insurance.
	 	 
		The work can entail both overtime and travel in the service. JOHANSSON does not have the
                                                                                right to overtime or travel time allowance, which should be considered included and paid in full through regular salary.
	 	 
		Sick pay is paid in accordance with current legislation.

 

	2.2	Review and possible salary adjustments are made annually on 1 May.

 

	2.3	The right to a bonus for JOHANSSON, if applicable, is agreed in a separate written agreement between the parties and does not
form part of the employment contract.

 

	2.4	Johansson is entitled to participate in the existing warrant program at terms and allocation decided by the Board of Directors.

 

	3.	Vacation

 

		JOHANSSON is entitled to 30 days paid vacation per year. Paid holidays are earned
                                                      in the usual way and must be taken in agreement with the company's CEO.

 

	4.	Work tools etc.

 

	4.1	For the execution of JOHANSSON's duties, the Company provides equipment that is essential for the execution of the work. Currently,
this means laptop and mobile phone.

 

	4.2	JOHANSSON is entitled to reimbursement for reasonable expenses for representation after the approval of the CEO.

 

	4.3	JOHANSSON shall comply with the Company's policy regarding outlays and shall report all receipts no later than the month after
the outlays were made. JOHANSSON is not entitled to compensation for expenses unless JOHANSSON is able to present a receipt for
the expenses.

 

     

     

    

 

	5.	Loyalty etc.

 

		JOHANSSON has to monitor and safeguard the Company's interests at all times.
                                                      JOHANSSON is not entitled to carry out work or, directly or indirectly, to pursue or have a financial interest in activities
                                                      that compete with the activities that the Company conducts from time to time. Furthermore, JOHANSSON shall not undertake any
                                                      assignment that, by its scope or nature, may adversely affect the performance of the employment.

 

	6.	Privacy

 

		JOHANSSON undertakes, without time limit, not to use confidential
information regarding the Company, its operations, customers or partners, with third parties or for own use. For the purposes
of this Agreement, “confidential information” means any information, whether technical, commercial or other, whether
documented or not, with the exception of information that is or becomes widely known or that has come or is widely publicized
in other ways JOHANSSON's violation of this provision.

 

	7.	Prohibition of competition

 

	7.1	The parties agree that JOHANSSON, through its position in the Company, will disclose corporate secrets that cannot be protected
by patents or similar registration procedures, and whose use in competing activities would result in significant but for the Company.
The parties also agree that it is a prerequisite for the Company, in confidence, to submit such information to JOHANSSON that the
Company can ensure that JOHANSSON does not use the knowledge and contacts obtained through the employment to build or operate in
operations that compete with the Company or its affiliates. It is therefore incumbent upon JOHANSSON to, during the term of the
Employment Agreement and for nine (9) months from termination of employment, either himself or as owner, partner, board member,
adviser or employee of another company, either directly or indirectly with the Company, or with its affiliates, competing operations.

 

	7.2	Except in the cases mentioned below, the Company shall pay JOHANSSON a monthly payment in arrears, as compensation for the
inconvenience of the competitive prohibition on competition. The compensation shall be calculated as the difference of the income
that JOHANSSON subsequently earns, or could reasonably have earned in a new employment or other employment, and the average compensation
received (including both fixed salary and variable remuneration) in the last 12 months before termination of employment. However,
the remuneration from the Company shall never exceed sixty (60) per month of JOHANSSON's average monthly remuneration per month
during the period when the prohibition on competition applies. In the event that JOHANSSON, despite reasonable measures to limit
its loss of income, does not receive new employment or engage in other employment activities after termination of employment, compensation
is paid monthly by sixty (60) percent of JOHANSSON's average monthly compensation as set out above during the period of the competitive
ban. The right to compensation from the Company in accordance with this paragraph assumes that there is a causal link between JOHANSSON's
commitment to prohibit competition and the loss of income arising from its application. Compensation is not paid if JOHANSSON violates
the prohibition on competition.

 

     

     

    

 

	7.3	After the termination of employment, JOHANSSON shall keep the Company informed of the size of its income from new employers
or other business activities. Such notification shall be made in writing to the Company no later than the 15th of each month. If
this does not happen, it is assumed that JOHANSSON has not suffered any loss of income for that month, without the restriction
of competition according to point 7.1, for that reason.

 

	7.4	Compensation under this paragraph shall not be paid for the period during which JOHANSSON may receive severance pay from the
Company or if the employment terminates due to: (i) JOHANSSON's retirement or (ii) cancellation of the Employment Agreement or
the Company has terminated JOHANSSON.

 

	7.5	Both during the employment and after either party's termination of employment and as long as the prohibition on competition
is in force, the Company can unilaterally, through notification to JOHANSSON, limit the scope of the prohibition on competition
or completely free JOHANSSON from the obligation to comply with the prohibition on competition. In the event that the Company completely
exempts JOHANSSON from the obligation to comply with the prohibition on competition, the Company's liability under paragraph 7.2
above shall cease to apply. The company's possible exemption from the competition ban must be given with one month's notice period.

 

	8.	Employment and customer prohibitions

 

	8.1	The parties agree that during the term of employment of the Employment Agreement and for twelve (12) months from termination
of employment, JOHANSSON must not have, in person or through any other, business contacts with any person or company, which during
the last twelve months prior to the employment cessation has been a customer of, or actively processed by, the Company or its affiliated
companies, with the aim of causing such customer / potential customer to change, terminate or not enter into a commercial relationship
with the Company or its affiliates. However, upon request from JOHANSSON, the Company may, in written confirmation, in individual
cases release JOHANSSON from this undertaking.

 

	8.1	The parties further agree that during the term of the Employment Agreement and for twelve (12) months from termination of employment,
JOHANSSON may not employ, either personally or through any other person, any person employed or employed by the Company or its
affiliates or utilize their services other than through the Company. However, upon request from JOHANSSON, the Company may, in
written confirmation, in individual cases release JOHANSSON from this undertaking.

 

	9.	Time reporting etc. and policies

 

		JOHANSSON undertakes to comply with the Company's policy on time reporting, IT security, use
                                                          of e-mail and the Internet, travel etc.

 

	10.	Results

 

		All results, including all information, data, know-how, inventions or equivalent and all
                                                    related intellectual property rights that lie within the Company's business areas and which arise through JOHANSSON's care or
                                                    participation during the period of employment ("Result") shall immediately belong to the Company with full and
                                                    unrestricted ownership without any other compensation to JOHANSSON other than ordinary salary under this Agreement. At the
                                                    Company's request, JOHANSSON shall confirm transfer of Results in a separate written document where appropriate or necessary
                                                    for, for example, seeking intellectual property protection or carrying out a transaction.

 

	11.	Personal data

 

		In order to administer this employment contract and to be able to carry out work management
                                                   and conduct the business in an appropriate manner, the Company will process JOHANSSON's personal data with the help of, among
                                                   other things. computers. The personal information consists of JOHANSSONs, social security number, telephone number, home
                                                   address, other contact details, bank account details, etc. The Company may also publish JOHANSSON's name, position, telephone
                                                   number, e-mail address and a photo on JOHANSSON on the Company's website.

 

     

     

    

 

		JOHANSSON hereby submits its approval to the Company's processing of JOHANSSON's personal
                                                          data as above.

 

	12.	Termination

 

	12.1	Mutual notice period of 6 months is applied.

 

	12.2	Upon termination of employment, JOHANSSON shall hand over to the Company all material and property of the Company for which
JOHANSSON has possession or otherwise is responsible. This includes keys, documents and documents (both in paper form and digital),
computer, mobile phone, software etc.

 

	13.	Penalty

 

		Should JOHANSSON violate the provisions of Articles 5, 6, 8 and 10, in addition to damages
                                                       for actual damage, the company shall also be entitled to receive a penalty of at least three months' salary for each
                                                       violation.

 

	14.	Law 

 

		Swedish law shall apply to this agreement.

 

 

 

This agreement has been drawn up in two
similar copies, each of which the parties have taken separately.

 

	Stockholm 24/7 2017	 	Stockholm 24/7 2017

	 

	 

	Calliditas	Therapeutics AB
	 	 
	 	 

	/s/ Renée Aguiar-Lucander	 	/s/ Fredrik Johansson

	Renée Aguiar-Lucander, CEO 	 	Fredrik Johansson

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}]]